

---

---

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

---

FORM 8-K

CURRENT REPORT  
Pursuant to Section 13 or 15(d) of the  
Securities Exchange Act of 1934

Date of Report (Date of earliest event reported):  
November 7, 2013 (November 7, 2013)

---

**HARRIS & HARRIS GROUP, INC.**

---

(Exact name of registrant as specified in its charter)

**New York**  
(State or other jurisdiction of  
incorporation)

**0-11576**  
(Commission File  
Number)

**13-3119827**  
(IRS Employer  
Identification No.)

---

**1450 Broadway**  
**New York, New York 10018**

---

(Address of principal executive offices and zip code)

**(212) 582-0900**

---

(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
- 
-

**Item 8.01. Other Events.**

On November 7, 2013, Harris & Harris Group, Inc. (the "Company") noted CordenPharma's acquisition of Ancora Pharmaceuticals' carbohydrate synthesis technology platform and the use of the corporate name of Ancora Pharmaceuticals. Ancora's technology and chemistry research facilities complement CordenPharma's capabilities in the manufacture and supply of high-quality complex synthetic molecules. The remaining assets of Ancora will be maintained under the corporate name SynGlyco, Inc. The Company's press release is attached hereto as Exhibit 99.1.

**Item 9.01. Financial Statements and Exhibits.**

- (a) Not applicable.
- (b) Not applicable.
- (c) Not applicable.
- (d) Exhibits.

<u>Exhibit No.</u>	<u>Description</u>
99.1	Press Release dated November 7, 2013

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: November 7, 2013

HARRIS & HARRIS GROUP, INC.

By: /s/ Douglas W. Jamison  
Douglas W. Jamison  
Chief Executive Officer

---

EXHIBIT INDEX

<u>Exhibit No.</u>	<u>Description</u>
99.1	Press Release dated November 7, 2013

---

**PRESS RELEASE**

**FOR IMMEDIATE RELEASE**

**HARRIS & HARRIS GROUP, INC.®**  
**1450 BROADWAY, 24<sup>TH</sup> FLOOR**  
**NEW YORK, NY 10018**  
**TEL. NO. (212) 582-0900**

**NOVEMBER 7, 2013**

**CONTACT: DOUGLAS W. JAMISON**

**Harris & Harris Group Notes CordenPharma's Acquisition  
of Ancora's Carbohydrate Synthesis Platform and Corporate Name**

Harris & Harris Group, Inc. (NASDAQ: TINY), an investor in transformative companies enabled by disruptive science, notes CordenPharma's acquisition of Ancora Pharmaceuticals' carbohydrate synthesis technology platform and the use of the corporate name of Ancora Pharmaceuticals. Ancora's technology and chemistry research facilities complement CordenPharma's capabilities in the manufacture and supply of high-quality complex synthetic molecules.

As a result of the acquisition, Ancora's extensive know-how and historical expertise in carbohydrate synthesis will be merged with CordenPharma's process development, scale-up and cGMP manufacturing capabilities. This acquisition is a key step in CordenPharma's strategy to become the leading global supplier of synthetic carbohydrates for all applications, including glycoconjugate vaccine antigens, immunomodulatory therapeutics, tissue targeting/drug delivery motifs, nutraceuticals, analytical reagents and standards, diagnostic reagents, and defined content for glycomics research.

Together, Ancora and CordenPharma are now equipped to provide carbohydrate synthesis and production needs from early-stage discovery research through to commercial cGMP manufacturing at any scale. Both CordenPharma and Ancora will serve customers out of Ancora's Woburn, MA, facility, with newly expanded capabilities for seamless transition to large scale cGMP manufacturing at CordenPharma's facilities in the United States and Europe. While the Ancora brand will remain, inquiries will be evaluated and handled in coordination with CordenPharma in an effort to comprehensively cover all aspects from chemistry development to large-scale GMP manufacturing. CordenPharma's press release can be viewed at <http://cordenpharma.com/cordenpharma-acquires-ancora-pharmaceuticals/>.

"We are excited for Ancora to join CordenPharma, which will expand Ancora's chemistry expertise into an organization that can provide scale and cGMP manufacturing of complex synthetic carbohydrates," said Dr. Misti Ushio, Executive Vice President and Managing Director of Harris & Harris Group and Chairperson of Ancora Pharmaceuticals.

The remaining assets of Ancora will be maintained under the corporate name SynGlyco, Inc.

Detailed information about Harris & Harris Group and its holdings can be found on its website at [www.HHVC.com](http://www.HHVC.com) and on Facebook at [www.facebook.com/harrisharrisvc](http://www.facebook.com/harrisharrisvc).

This press release may contain statements of a forward-looking nature relating to future events. These forward-looking statements are subject to the inherent uncertainties in predicting future results and conditions. These statements reflect the Company's current beliefs, and a number of important factors could cause actual results to differ materially from those expressed in this press release. Please see the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2012, as well as subsequent filings, filed with the Securities and Exchange Commission for a more detailed discussion of the risks and uncertainties associated with the Company's business, including, but not limited to, the risks and uncertainties associated with venture capital investing and other significant factors that could affect the Company's actual results. Except as otherwise required by Federal securities laws, the Company undertakes no obligation to update or revise these forward-looking statements to reflect new events or uncertainties. The references to the websites [www.HHVC.com](http://www.HHVC.com), [www.Facebook.com](http://www.Facebook.com), and [www.cordenpharma.com](http://www.cordenpharma.com) have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. Harris & Harris Group is not responsible for the contents of third party websites.

---